Casirivimab and Imdevimab for the Treatment of Hospitalized Patients With COVID-19.
Somersan-Karakaya S, Mylonakis E, Menon VP, Wells JC, Ali S, Sivapalasingam S, Sun Y, Bhore R, Mei J, Miller J, Cupelli L, Forleo-Neto E, Hooper AT, Hamilton JD, Pan C, Pham V, Zhao Y, Hosain R, Mahmood A, Davis JD, Turner KC, Kim Y, Cook A, Kowal B, Soo Y, DiCioccio AT, Geba GP, Stahl N, Lipsich L, Braunstein N, Herman GA, Yancopoulos GD, Weinreich DM; COVID-19 Phase 2/3 Hospitalized Trial Team.
Somersan-Karakaya S, et al. Among authors: stahl n.
J Infect Dis. 2022 Dec 28;227(1):23-34. doi: 10.1093/infdis/jiac320.
J Infect Dis. 2022.
PMID: 35895508
Free PMC article.
Clinical Trial.